Ultragenyx Pharmaceutical Inc (NAS:RARE)
$ 41.87 -0.74 (-1.74%) Market Cap: 3.48 Bil Enterprise Value: 3.17 Bil PE Ratio: 0 PB Ratio: 25.24 GF Score: 70/100

Ultragenyx Pharmaceutical Inc at JPMorgan Healthcare Conference (Virtual) Transcript

Jan 10, 2022 / 08:45PM GMT
Release Date Price: $73.1 (-0.94%)
Cory William Kasimov
JPMorgan Chase & Co, Research Division - Senior Biotechnology Analyst

All right. Good afternoon, everyone. Welcome to the 40th Annual JPMorgan Healthcare Conference. My name is Cory Kasimov. I'm the senior large-cap biotech analyst. And it's my pleasure to introduce Ultragenyx and the company's CEO, Emil Kakkis.

And please note that following the presentation, we'll move directly into a Q&A session where you can send in your own questions via the conference portal, and I'll do my best to work these into the conversation.

So Emil, thanks, as always, for joining us. And let me turn things over to you for an update.

Emil D. Kakkis
Ultragenyx Pharmaceutical Inc. - President, CEO & Director

Thanks very much, Cory. Good to see you and good to see everyone. I know it's been a busy day and a lot going on, but I'm happy to give you an update on Ultragenyx and where we are today.

If you go past the cover slide, you'll see our legal warning regarding investment in Ultragenyx. And going to the third slide, we

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot